Circulating ACE2: a novel biomarker of cardiovascular risk
Open Access
- 1 October 2020
- journal article
- editorial
- Published by Elsevier BV in The Lancet
- Vol. 396 (10256), 937-939
- https://doi.org/10.1016/s0140-6736(20)32011-0
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Plasma ACE2 Activity Predicts Mortality in Aortic Stenosis and Is Associated With Severe Myocardial FibrosisJACC: Cardiovascular Imaging, 2019
- Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery diseasePLOS ONE, 2018
- Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodellingEP Europace, 2016
- Assessing the cost effectiveness of using prognostic biomarkers with decision models: case study in prioritising patients waiting for coronary artery surgeryBMJ, 2010
- Detection of Soluble Angiotensin-Converting Enzyme 2 in Heart Failure: Insights Into the Endogenous Counter-Regulatory Pathway of the Renin-Angiotensin-Aldosterone SystemJournal of the American College of Cardiology, 2008
- Biomarkers of Cardiovascular DiseaseCirculation, 2006
- A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injuryNature Medicine, 2005
- ACE2, a new regulator of the renin–angiotensin systemTrends in Endocrinology & Metabolism, 2004
- Angiotensin-converting enzyme 2 is an essential regulator of heart functionNature, 2002
- A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9Circulation Research, 2000